CTS Corporation has finalized its acquisition of Millar Holdings for $50 million, enhancing its capabilities in advanced pressure sensing technologies used in medical, life sciences, and industrial fields. This strategic move expands CTS's presence in diversified markets and strengthens its position in medical sensing technology. The acquisition brings Millar's innovative technology, skilled workforce, and strong customer relationships under CTS, aiming to accelerate innovation and create long-term shareholder value. Both companies express optimism about future growth and expanded capabilities through this partnership.
CTS Corporation's acquisition of Millar Holdings is reported alongside Pluang's snapshot of the Technology sector. For readers following this sector, as of Oct 23, 2026 21:31 WIB, 64 of 150 priced US Technology stocks rose while 85 fell. Notable movers include Nokia Corp (NOK) with a price of USD 8.23 and a 1-day change of +4.57%, Wipro Limited (WIT) at USD 2.09 down -4.57%, and Okta, Inc. (OKTA) at USD 209.99 up +4.30%. Typical hold times range from 41 to 66 days, with varying Pluang order activity percentages.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
